Combo of Approved Agents Active in High-Risk Large B-Cell Lymphoma

Published Date: 28 Jun 2024

Our panel of experts discusses mosunetuzumab/polatuzumab vedotin for relapsed/refractory patients

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

'Full House' Star's Cancer; Fluoride Fears Go Mainstream; Florida Doctor Arrested

2.

Combo of Approved Agents Active in High-Risk Large B-Cell Lymphoma

3.

Vaccine elicits strong immune response in patients with pancreatic and colorectal cancer

4.

A new therapeutic approach could help tackle radiation resistance in childhood brain tumors

5.

Stem Cell Selection Unneeded for SSc Transplant Therapy?


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot